Provide dialysis products (dialyzers, machines) and services for chronic kidney failure patients through Fresenius Medical Care. Now — the numbers.
This is an established company with proven profits.
An average decline of 13% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
The gap is $12.0B. In times of high interest rates, a gap like that can squeeze a company.
The market pays 83.7× for every dollar this company earns in a year — a price that already assumes things go well.
Analysts' average target sits 29% below today's price.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
The stock trades 42% below its peak. The market has trimmed its expectations for the company.
It pays out $0.30 per share each year — regular cash for whoever holds the stock.
Over the last 4 years, sales fell about 13% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
The company’s market value is 84 times its annual profit. Even a small disappointment could hit the price hard.
The stock trades 29% above the average analyst price target.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.